Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "ArtifactAssessment",
"id" : "179469",
"meta" : {
"versionId" : "18",
"lastUpdated" : "2024-12-12T13:34:30.038Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-justification"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Title: </b>Justification for Recommendation: ADA Obesity Management Recommendation 8.16</p><br/><p><b>Justification for Recommendation: </b>Recommendation: ADA Obesity Management Recommendation 8.16</p><br/><table><tr><th>Concept</th><th>Summary</th><th>Rating</th></tr><tr><td>Recommendation Specification (coded as: RJCS-content0 from https://fevir.net/resources/CodeSystem/27834); Recommendation Specification (coded as: recommendation-specification from https://fevir.net/resources/CodeSystem/179423)</td><td>8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans) and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A</td><td>undefined</td></tr><tr><td>Rating System (coded as: rating-system from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>ADA Level of Evidence</td></tr><tr><td>Strength of Recommendation (coded as: RJCS-1000 from https://fevir.net/resources/CodeSystem/27834); Strength of Recommendation (coded as: strength-of-recommendation from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Direction of Recommendation (coded as: RJCS-1014 from https://fevir.net/resources/CodeSystem/27834); Direction of Recommendation (coded as: direction-of-recommendation from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>Favors intervention (coded as: RJCS-2021 from https://fevir.net/resources/CodeSystem/27834)</td></tr><tr><td>Ratings (coded as: ratings from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>A</td></tr><tr><td>Evidence (coded as: RJCS-content1 from https://fevir.net/resources/CodeSystem/27834); Evidence (coded as: evidence from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Summary of Findings (coded as: summary-of-findings from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Desirable Effects (coded as: RJCS-1004 from https://fevir.net/resources/CodeSystem/27834); Desirable Effects (coded as: desirable-effects from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Undesirable Effects (coded as: RJCS-1005 from https://fevir.net/resources/CodeSystem/27834); Undesirable Effects (coded as: undesirable-effects from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td><td>A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.<br/>In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.</td><td>undefined</td></tr><tr><td>Net Effect (coded as: RJCS-1007 from https://fevir.net/resources/CodeSystem/27834); Net Effect (coded as: net-effect from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Values/Preferences (coded as: RJCS-1006 from https://fevir.net/resources/CodeSystem/27834); Preferences (coded as: preferences from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Judgments (coded as: RJCS-content2 from https://fevir.net/resources/CodeSystem/27834); Judgments (coded as: judgments from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Justification (coded as: justification from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Problem Importance (coded as: RJCS-1003 from https://fevir.net/resources/CodeSystem/27834); Problem Importance (coded as: problem-importance from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Resources/Costs (coded as: RJCS-1008 from https://fevir.net/resources/CodeSystem/27834); Costs (coded as: costs from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Cost-effectiveness (coded as: RJCS-1009 from https://fevir.net/resources/CodeSystem/27834); Cost-effectiveness (coded as: cost-effectiveness from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Equity (coded as: RJCS-1010 from https://fevir.net/resources/CodeSystem/27834); Equity (coded as: equity from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Acceptability (coded as: RJCS-1011 from https://fevir.net/resources/CodeSystem/27834); Acceptability (coded as: acceptability from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Feasibility (coded as: RJCS-1012 from https://fevir.net/resources/CodeSystem/27834); Feasibility (coded as: feasibility from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Competing Interests (coded as: RJCS-1002 from https://fevir.net/resources/CodeSystem/27834); Competing Interests (coded as: competing-interests from https://fevir.net/resources/CodeSystem/179423)</td><td>All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes—2021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</td><td>undefined</td></tr></table><br/></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-url",
"valueUri" : "https://fevir.net/resources/ArtifactAssessment/179469"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-description",
"valueMarkdown" : "An example using the ArtifactAssessment Resource for representation of the many judgments and concepts used to justify a recommendation."
}
],
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "urn:ietf:rfc:3986",
"value" : "https://fevir.net/FOI/179469",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "Justification for Recommendation: ADA Obesity Management Recommendation 8.16",
"citeAsMarkdown" : "Justification for Recommendation: ADA Obesity Management Recommendation 8.16 [Database Entry: FHIR ArtifactAssessment Resource]. Contributors: In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179469. Revised 2024-07-02. Available at: https://fevir.net/resources/ArtifactAssessment/179469. Computable resource at: TBD#json.",
"artifactReference" : {
🔗 "reference" : "Composition/179466",
"type" : "Composition",
"display" : "Recommendation: ADA Obesity Management Recommendation 8.16"
},
"content" : [
{
"summary" : "8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans) and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-content0",
"display" : "Recommendation Specification"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "recommendation-specification",
"display" : "Recommendation Specification"
}
]
},
"relatedArtifact" : [
{
"type" : "derived-from",
"classifier" : [
{
"text" : "Guideline"
},
{
"text" : "Citation Resource"
}
],
"citation" : "8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021 [Journal Article]. Contributors: American Diabetes Association. In: Diabetes care, PMID 33298419. Published January 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/33298419/.",
"resourceReference" : {
🔗 "reference" : "Citation/32137",
"type" : "Citation",
"display" : "JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes"
}
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "rating-system",
"display" : "Rating System"
}
]
},
"classifier" : [
{
"text" : "ADA Level of Evidence"
}
],
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1000",
"display" : "Strength of Recommendation"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "strength-of-recommendation",
"display" : "Strength of Recommendation"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1014",
"display" : "Direction of Recommendation"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "direction-of-recommendation",
"display" : "Direction of Recommendation"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-2021",
"display" : "Favors intervention"
}
]
}
],
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ratings",
"display" : "Ratings"
}
]
},
"classifier" : [
{
"text" : "A"
}
],
"freeToShare" : true
}
]
},
{
"summary" : "ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-content1",
"display" : "Evidence"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence",
"display" : "Evidence"
}
]
},
"relatedArtifact" : [
{
"type" : "justification",
"classifier" : [
{
"text" : "Guideline"
},
{
"text" : "Citation Resource"
}
],
"citation" : "Rubino\u2008F, Nathan\u2008DM, Eckel\u2008RH, et al.; Delegates of the 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care\u20082016;39:861–877",
"resourceReference" : {
🔗 "reference" : "Citation/33089",
"type" : "Citation",
"display" : "JournalArticleCitation: Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations"
}
},
{
"type" : "justification",
"classifier" : [
{
"text" : "Evidence Resource"
}
],
"citation" : "derived from Figure 2C of: Rubino\u2008F, Nathan\u2008DM, Eckel\u2008RH, et al.; Delegates of the 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care\u20082016;39:861–877",
"resourceReference" : {
🔗 "reference" : "Evidence/33244",
"type" : "Evidence",
"display" : "ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis"
}
}
],
"freeToShare" : true,
"component" : [
{
"summary" : "ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings",
"display" : "Summary of Findings"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1004",
"display" : "Desirable Effects"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "desirable-effects",
"display" : "Desirable Effects"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1005",
"display" : "Undesirable Effects"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "undesirable-effects",
"display" : "Undesirable Effects"
}
]
},
"freeToShare" : true
},
{
"summary" : "A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.<br/>In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "discussion",
"display" : "Discussion"
}
]
},
"relatedArtifact" : [
{
"type" : "justification",
"classifier" : [
{
"text" : "Citation"
}
],
"citation" : "Sjöström\u2008L, Peltonen\u2008M, Jacobson\u2008P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA\u20082014;311:2297–2304"
},
{
"type" : "justification",
"classifier" : [
{
"text" : "Citation"
}
],
"citation" : "Aminian\u2008A, Zajichek\u2008A, Arterburn\u2008DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA\u20082019;322:1271–1282"
},
{
"type" : "justification",
"classifier" : [
{
"text" : "Evidence Resource"
}
],
"resourceReference" : {
🔗 "reference" : "Evidence/32144"
}
}
],
"freeToShare" : true
}
]
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1007",
"display" : "Net Effect"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "net-effect",
"display" : "Net Effect"
}
]
},
"freeToShare" : true,
"component" : [
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1006",
"display" : "Values/Preferences"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "preferences",
"display" : "Preferences"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "discussion",
"display" : "Discussion"
}
]
},
"freeToShare" : true
}
]
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-content2",
"display" : "Judgments"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "judgments",
"display" : "Judgments"
}
]
},
"freeToShare" : true,
"component" : [
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "justification",
"display" : "Justification"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1003",
"display" : "Problem Importance"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "problem-importance",
"display" : "Problem Importance"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1008",
"display" : "Resources/Costs"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "costs",
"display" : "Costs"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1009",
"display" : "Cost-effectiveness"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "cost-effectiveness",
"display" : "Cost-effectiveness"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1010",
"display" : "Equity"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "equity",
"display" : "Equity"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1011",
"display" : "Acceptability"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "acceptability",
"display" : "Acceptability"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1012",
"display" : "Feasibility"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "feasibility",
"display" : "Feasibility"
}
]
},
"freeToShare" : true
}
]
},
{
"summary" : "All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes—2021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-1002",
"display" : "Competing Interests"
},
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "competing-interests",
"display" : "Competing Interests"
}
]
},
"freeToShare" : true
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change